| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 8,690 | 7,380 | 6,720 | 7,050 | 6,550 |
| Sales Growth | +17.75% | +9.82% | -4.68% | +7.63% | +6.68% |
| Net Income | -3,410 | -3,670 | -3,860 | -3,230 | -2,500 |
| Net Income Growth | +7.08% | +4.92% | -19.50% | -29.20% | +6.02% |
Electrocore Inc (ECOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
electroCore Inc. is a commercial-stage bioelectronic medicine company. Its current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache. electroCore Inc., formerly known as ELECTROCORE LLC, is based in LOS ANGELES, CA.
Fiscal Year End Date: 12/31